Analysis

Novo Nordisk is discontinuing Saxenda, with last shipments to wholesalers in late January 2027. Victoza stays on the market, and so do the Hikma, Meitheal and Teva-distributed generic liraglutide lines. No FDA label publishes a dose conversion from liraglutide to semaglutide or tirzepatide, and that absence is the most useful fact for anyone planning a switch.

Updated August 5, 2026: Added Lilly's ClinicalTrials.gov expanded-access record (NCT07629401), registered June 5, 2026, which lists no eligibility criteria. Biologic classification lawsuit context (Lilly v. FDA, Case 1:24-cv-01503). Obesity (TRIUMPH-1): 28.3% weight loss at 80 weeks, 30.3% at 104 weeks, 65.3% achieved BMI <30. T2D (TRANSCEND-T2D-1): A1C −2.0%, weight −16.8%. NDA expected Q4 2026. Court ruling: FDA's bright-line classification of retatrutide as a drug (not biologic) vacated. Outcome determines whether compounding can legally exist post-approval.

Serena Williams disclosed GLP-1 treatment and a commercial Ro relationship in 2025, then returned to professional tennis in 2026. No cited official source confirms current Zepbound use. Here is the dated evidence and the difference between WADA monitoring and prohibition.

A Penn-led analysis compared seven cardiometabolic outcomes across GLP-1 trial programs, while Mayo researchers identified a possible obesity phenotype associated with a different retrospective tirzepatide response. Together they sharpen the research questions, but they do not create a consumer test or treatment selector.

Berberine picked up the nickname "nature's Ozempic" on TikTok. The two compounds act on different targets, and the meta-analysis that looked directly at body weight found no significant effect.

A weight plateau on semaglutide or tirzepatide has four separate causes, and they do not share an answer. Here is how to tell which one you are looking at, using what the STEP and SURMOUNT trials actually measured.

Clinical trials show 14.9-20.7% body weight loss with semaglutide depending on dose. Standard Wegovy (2.4mg): 14.9-17% over 68 weeks. Wegovy HD (7.2mg, FDA-approved March 2026): 20.7% over 72 weeks. Month-by-month breakdown from the STEP trials.

Updated August 14, 2026: Oral Wegovy produced 16.6% weight loss in OASIS vs Foundayo's 12.4% in ATTAIN-1; these were separate trials. Both manufacturer-direct cash-pay floors now start at $149/mo. Foundayo follows a $149-$349 dose/refill ladder and requires no fasting; NovoCare's Wegovy pill price is dose-dependent and requires a 30-minute pre-dose fast.

Updated August 2026: Tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% in the SURMOUNT-5 head-to-head trial (NEJM 2024): a 47% greater relative reduction confirmed by 2026 systematic meta-analyses. Tirzepatide activates GLP-1 + GIP dual receptors; semaglutide activates GLP-1 only. Full cost and side-effect comparison.

Updated August 2026: SURMOUNT-5 head-to-head trial (NEJM): Zepbound 20.2% vs Wegovy 13.7% weight loss at 72 weeks. Wegovy HD (7.2mg, FDA-approved March 2026) closes the gap at 20.7%. NovoCare lists the Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and pill from $149/mo, prescription required and dose-dependent; LillyDirect lists Zepbound from $299/mo with higher-dose pricing. Both may be as low as $25/mo for eligible commercially insured patients using a savings card.

How much do GLP-1 medications cost in 2026? Wegovy, Zepbound, Ozempic, Mounjaro & Foundayo range from $25 to $1,350/month. With insurance + savings card: $25/mo. Without insurance: $146/mo compounded sema (Yucca Health), $149/mo Foundayo pill, $299 to 449/mo brand injectable (LillyDirect, NovoCare). Medicare: $50/mo, live as of July 2026. Prices verified July 2026 across 53 providers.

Verified August 14, 2026: Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic ($1,027.51/mo list) is approved for type 2 diabetes at max 2mg. Wegovy ($1,349/mo list) is approved for weight loss at max 2.4mg (or 7.2mg HD). NovoCare lists each pen at $199/mo for the first two low-dose fills; Wegovy then costs $349/mo at standard strengths ($399 HD), while Ozempic costs $349/mo at 0.25-1mg or $499/mo at 2mg. Pills start at $149/mo and are dose-dependent.

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved only for type 2 diabetes, neither is approved for weight loss (that's their sister brands, Zepbound and Wegovy). In the first head-to-head trial, SURMOUNT-5, tirzepatide beat semaglutide for weight loss (−20.2% vs −13.7% over 72 weeks), and in SURPASS-2 tirzepatide cut A1C more. But Ozempic's semaglutide has the SELECT cardiovascular outcome data Mounjaro doesn't. Here's the data-driven breakdown, plus the cheaper cash-pay paths if your insurance says no.

CagriSema (cagrilintide + semaglutide) lost 22.7% average body weight in adults with obesity (REDEFINE 1) and 13.7% in adults with type 2 diabetes (REDEFINE 2) over 68 weeks. Novo Nordisk filed its US application on December 18, 2025; an FDA decision is expected later in 2026 with no public PDUFA date. It is not FDA-approved and not legally available as of June 2026, here is the honest data, how it stacks up against drugs you can get today, and why every site selling 'CagriSema' right now is a red flag.

IvyRx offers compounded semaglutide from $175/month and tirzepatide from $275/month with a rare flat-rate model, your price never increases as your dose goes up. We reviewed their pricing, clinical oversight, and transparency. Key finding: the flat-rate pricing is genuinely valuable, but IvyRx doesn't publicly disclose a named medical director or their compounding pharmacy partners, which are meaningful gaps for patients who want to verify clinical quality.

Updated May 2026: 5 next-gen obesity drugs in Phase 3. Retatrutide (Lilly) 28.7% weight loss. CagriSema (Novo): REDEFINE-1 22.7% (obesity), REDEFINE-2 15.7% (T2D), PDUFA expected October 2026. MariTide (Amgen, monthly), survodutide, Foundayo approved April 2026. FDA approvals 2026-2028.

Verified July 2026: Zepbound and Mounjaro are the exact same drug (tirzepatide) at the same doses. Mounjaro was FDA-approved May 2022 for Type 2 diabetes. Zepbound was FDA-approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea. List price is ~$1,087/mo for both; with commercial insurance + savings cards both drop to $25/mo (max $1,950/yr). The real differences: which one your insurance covers, what the FDA label allows, and Zepbound's LillyDirect self-pay vials at $299-$449/mo, a program Mounjaro does not offer.

Verified August 7, 2026: NovoCare lists the brand-name Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and the oral pill from $149/mo, dose-dependent; Zepbound starts at $299/mo via LillyDirect. Compounded offerings may advertise lower prices but require product- and prescription-specific regulatory review.

Verified August 2026: Oral Wegovy (25mg daily pill) produced 16.6% weight loss in OASIS vs 14.9% for injectable Wegovy (2.4mg weekly) in STEP-1. NovoCare lists the pill from $149/mo and pen from $199/mo, prescription required and dose-dependent. Full cross-trial comparison.

Verified August 2026: Tirzepatide prices include $149/mo via Gala on a yearly microdose plan ($169/mo for 3 months), $299/mo via LillyDirect (brand Zepbound 2.5mg vial), $399 for the 5mg vial, $449 for 7.5mg and higher doses when refill conditions are met, $25/mo with an eligible Zepbound savings card, or $1,086/mo retail list price. Full price breakdown with 54 tracked providers.

Tirzepatide's shortage was resolved in October 2024 and shortage-based enforcement discretion ended in early 2025. This guide compares advertised compounded prices with brand Zepbound and explains why legality, formulation, and safety cannot be inferred from availability alone.

GLP-1 patches sold online don't contain semaglutide or tirzepatide, they're herbal supplements. Here's what the science says and what actually works.

Two of the biggest telehealth platforms now offer branded Wegovy and GLP-1 programs. We compare Ro and Hims on pricing, medications, insurance, clinical support, and what actually changed after the Novo Nordisk lawsuit and the September 2025 FDA warning letter.